ES2067460T3 - Mevalonolactonas de tipo quinolina. - Google Patents

Mevalonolactonas de tipo quinolina.

Info

Publication number
ES2067460T3
ES2067460T3 ES88113448T ES88113448T ES2067460T3 ES 2067460 T3 ES2067460 T3 ES 2067460T3 ES 88113448 T ES88113448 T ES 88113448T ES 88113448 T ES88113448 T ES 88113448T ES 2067460 T3 ES2067460 T3 ES 2067460T3
Authority
ES
Spain
Prior art keywords
alkyl
hydrogen
phenyl
chem
together form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88113448T
Other languages
English (en)
Inventor
Yoshihiro Nissan Fujikawa
Mikio Nissan Suzuki
Hiroshi Nissan Iwasaki
Mitsuaki Nissan Chem Sakashita
Masaki Nissan Chemica Kitahara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nissan Chemical Corp
Original Assignee
Nissan Chemical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP63193606A external-priority patent/JP2569746B2/ja
Application filed by Nissan Chemical Corp filed Critical Nissan Chemical Corp
Application granted granted Critical
Publication of ES2067460T3 publication Critical patent/ES2067460T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA INVENCION SE REFIERE A UN COMPUESTO DE FORMULA(I), EN LA QUE R1, R2, R3, R4 Y R6 SON INDEPENDIENTEMENTE HIDROGENO, O DIVERSOS GRUPOS ALQUILICOS O ALCOXI, GRUPOS FLUORADOS, HALOGENOS, GRUPOS AROMATICOS, ALQUILSILOXI, GRUPOS FLUORADOS, HALOGENOS, GRUPOS AROMATICOS, ALQUILSILOXI, ETC O TIENEN DIVERSAS RELACIONES ENTRE ELLOS; Y ES UN GRUPO - CH2 -, - CH2CH2 -, - CH = CH -, - CH2 - CH = CH - O - CH = CH - CH2 -; Z ES - Q - CH2WCH2CO2R12, O LOS GRUPOS (II), (III) O (IV) (INDICANDOSE LOS SIGNIFICADOS POSIBLES DE Q, R11, R12, R13 Y R17); Y R5 ES HIDROGENO, ALQUILO DE 1 A 6 C, ALQUENILO DE 2 A 3 C, CICLOALQUILO DE 3 A 6 C, EL GRUPO(V), (DONDE R9 ES HIDROGENO, ALQUILO DE 1 A 4 C, ALCOXI DE 1 A 3 C, FLUOR, CLORO, BROMO O TRIFLUORMETILO), FENIL - (CH2)M - (SIENDO M 1, 2 O3), - (CH2)NCH(CH3) - FENILO O FENIL - (CH2)NCH(CH3) (DONDE N ES 1 O 2).
ES88113448T 1987-08-20 1988-08-18 Mevalonolactonas de tipo quinolina. Expired - Lifetime ES2067460T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP20722487 1987-08-20
JP1558588 1988-01-26
JP63193606A JP2569746B2 (ja) 1987-08-20 1988-08-03 キノリン系メバロノラクトン類

Publications (1)

Publication Number Publication Date
ES2067460T3 true ES2067460T3 (es) 1995-04-01

Family

ID=27281072

Family Applications (1)

Application Number Title Priority Date Filing Date
ES88113448T Expired - Lifetime ES2067460T3 (es) 1987-08-20 1988-08-18 Mevalonolactonas de tipo quinolina.

Country Status (7)

Country Link
EP (1) EP0304063B1 (es)
AT (1) ATE114645T1 (es)
CA (1) CA1336714C (es)
DE (1) DE3852243T2 (es)
ES (1) ES2067460T3 (es)
GR (1) GR3015186T3 (es)
HU (1) HU211700A9 (es)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ230121A (en) * 1988-08-29 1993-08-26 Squibb & Sons Inc Pyridine and quinoline terminal groups for hmg-coenzyme a reductase inhibitors and pharmaceutical compositions for lowering blood serum cholesterol levels
US5506219A (en) * 1988-08-29 1996-04-09 E. R. Squibb & Sons, Inc. Pyridine anchors for HMG-CoA reductase inhibitors
US5753675A (en) * 1989-03-03 1998-05-19 Novartis Pharmaceuticals Corporation Quinoline analogs of mevalonolactone and derivatives thereof
JP3528186B2 (ja) * 1991-06-24 2004-05-17 日産化学工業株式会社 光学活性キノリンメバロン酸のジアステレオマー塩
JP3130342B2 (ja) * 1991-10-04 2001-01-31 日産化学工業株式会社 動脈硬化性血管内膜肥厚抑制薬
TW232013B (es) * 1992-04-24 1994-10-11 Takeda Pharm Industry Co Ltd
US5455252A (en) * 1993-03-31 1995-10-03 Syntex (U.S.A.) Inc. Optionally substituted 6,8-quinolines
DE69422450T2 (de) * 1993-06-29 2000-06-08 Takeda Chemical Industries, Ltd. Chinoline oder Chinazolin-Derivate und deren Verwendung zur Herstellung eines Medikaments für die Behandlung von Osteoporose
US5475003A (en) * 1994-03-03 1995-12-12 Syntex (U.S.A.) Inc. 8-phenylcyclopentenoquinoline and 8-phenylcyclohexenoquinoline derivatives
DE19528418A1 (de) * 1995-08-02 1997-02-06 Merck Patent Gmbh Endothelin-Rezeptor-Antagonisten
WO1997023200A1 (en) * 1995-12-22 1997-07-03 Kowa Company, Ltd. Pharmaceutical composition stabilized with a basic agent
HRP970330B1 (en) * 1996-07-08 2004-06-30 Bayer Ag Cycloalkano pyridines
DE19709125A1 (de) * 1997-03-06 1998-09-10 Bayer Ag Substituierte Chinoline
DE19741051A1 (de) 1997-09-18 1999-03-25 Bayer Ag Hetero-Tetrahydrochinoline
SK288117B6 (sk) 1998-11-20 2013-09-03 Skyepharma Canada Inc. Rapidly dispersing solid dry therapeutic dosage form
KR100655671B1 (ko) * 1999-01-14 2006-12-08 닛산 가가쿠 고교 가부시키 가이샤 퀴놀린카르브알데히드의 제조 방법
US6855824B2 (en) 2000-02-21 2005-02-15 Kuraray Co., Ltd. Processes for preparing quinoline derivatives and intermediates thereof
KR100883874B1 (ko) 2001-02-02 2009-02-17 미쯔비시 가가꾸 가부시끼가이샤 (3ｒ,5ｓ)-(ｅ)-7-[2-시클로프로필-4-(4-플루오로페닐)-퀴노린-3-일]-3,5-디하이드록시헵트-6-엔산 에스테르류의 제조방법
TWI309644B (es) 2001-02-14 2009-05-11 Nissan Chemical Ind Ltd
UA76984C2 (en) 2001-04-05 2006-10-16 Nissan Chemical Ind Ltd A method for preparing a 7-qunolinyl-3,5-dihydroxyhept-6-enoate
JP4235000B2 (ja) 2001-04-19 2009-03-04 興和株式会社 糸球体疾患治療剤
US7193086B2 (en) 2001-05-30 2007-03-20 Nissan Chemical Industries, Ltd. Process for preparation of a quinolinecarbaldehyde
AU2003226971B2 (en) 2002-01-31 2006-11-30 Novartis Ag Process for the manufacture of HMG-CoA reductase inhibitors
GB0204129D0 (en) 2002-02-21 2002-04-10 Novartis Ag Process for the manufacture of organic compounds
ATE406447T1 (de) * 2002-03-19 2008-09-15 Mitsubishi Chem Corp Neue carbonylreduktase, diese codierendes gen und verfahren zur produktion optisch-aktiver alkohole damit
KR20050072798A (ko) * 2002-11-06 2005-07-12 닛산 가가쿠 고교 가부시키 가이샤 퀴놀린카르발데히드류의 제조 방법
DE202004021379U1 (de) 2003-02-12 2008-02-21 Ciba Specialty Chemicals Holding Inc. Kristalline Formen von Pitivastatin Calcium
EP1510208A1 (en) 2003-08-22 2005-03-02 Fournier Laboratories Ireland Limited Pharmaceutical composition comprising a combination of metformin and statin
TWI343914B (en) 2003-10-03 2011-06-21 Nissan Chemical Ind Ltd Process for producing high purity 3,5-dihydroxy-6-heptenoic acid derivative
RU2006124843A (ru) 2003-12-12 2008-01-20 Уайт (Us) Хинолины, пригодные для лечения сердечно-сосудистого заболевания
EP1719525B1 (en) * 2004-02-25 2014-12-10 Kowa Company, Ltd. Nuclear transfer promoter for cdc42 protein and method of screening the same
JP4711952B2 (ja) 2004-02-25 2011-06-29 興和株式会社 Ｒａｃタンパク質の核内移行促進剤及びそのスクリーニング方法
GB0427491D0 (en) * 2004-12-16 2005-01-19 Avecia Ltd Process and compounds
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US8455640B2 (en) 2006-05-03 2013-06-04 Msn Laboratories Limited Process for statins and its pharmaceutically acceptable salts thereof
EP2359826B1 (en) 2006-07-05 2013-10-30 Takeda GmbH Combination of HMG-COA reductase inhibitor rosuvastatin with a phosphodiesterase 4 inhibitor, such as roflumilast, roflumilast-N-oxide for the treatment of inflammatory pulmonary diseases
US8404841B2 (en) 2006-10-09 2013-03-26 Msn Laboratories Limited Process for the preparation of statins and their pharmaceutically acceptable salts thereof
ES2425969T3 (es) 2007-04-27 2013-10-18 Kyushu University, National University Corporation Agente para el tratamiento de enfermedades pulmonares
US8487105B2 (en) 2009-01-19 2013-07-16 Msn Laboratories Limited Process for preparing pitavastatin, intermediates and pharmaceuctically acceptable salts thereof
WO2011086584A2 (en) 2010-01-18 2011-07-21 Msn Laboratories Limited Improved process for the preparation of amide intermediates and their use thereof
US20120022102A1 (en) 2010-01-20 2012-01-26 Cadila Healthcare Limited Method for preparation of pitavastatin and its pharmaceutical acceptable salts thereof
US8372877B2 (en) 2010-04-16 2013-02-12 Cumberland Pharmaceuticals Stabilized statin formulations
TWI516264B (zh) * 2010-05-06 2016-01-11 臺北醫學大學 芳香醯喹啉化合物
WO2011141934A1 (en) 2010-05-13 2011-11-17 Matrix Laboratories Ltd. An improved process for the preparation of an intermediate of hmg-coa reductase inhibitors
JP5822169B2 (ja) 2010-07-01 2015-11-24 ユーハン・コーポレイションＹＵＨＡＮ Ｃｏｒｐｏｒａｔｉｏｎ ＨＭＧ−ＣｏＡ還元酵素阻害剤及びその中間体の製造方法
WO2012025939A1 (en) 2010-08-25 2012-03-01 Cadila Healthcare Limited Pitavastatin calcium and process for its preparation
EP2626069A4 (en) 2010-10-06 2014-03-19 Univ Tokyo Prophylactic and/or therapeutic agent against lymphedema
EA024991B1 (ru) 2011-09-12 2016-11-30 ФАРМА ДжРС, Д.О.О. Полиморфная форма питавастатина кальция
EP2785851A2 (en) 2011-11-28 2014-10-08 Mylan Laboratories, Limited Process for producing chiral statin side chain intermediates employing candida antarctica lipase b
CN103204807B (zh) * 2013-04-08 2015-12-23 黄河三角洲京博化工研究院有限公司 一种2-环丙基-4-（4-氟-苯基）-3-喹啉甲醛的合成方法
MX2015014666A (es) 2013-04-17 2016-03-01 Pfizer Derivados de n-piperidin-3-ilbenzamida para tratar enfermedades cardiovasculares.
WO2014203045A1 (en) 2013-06-20 2014-12-24 Lupin Limited A novel, green and cost effective process for synthesis of tert-butyl (3r,5s)-6-oxo-3,5-dihydroxy-3,5-o-isopropylidene-hexanoate
CN103483252B (zh) * 2013-09-04 2015-07-22 黄河三角洲京博化工研究院有限公司 一种2-环丙基-4-(4-氟苯基)-3-喹啉甲醇的合成方法
CN103508948A (zh) * 2013-10-17 2014-01-15 凯莱英医药集团（天津）股份有限公司 一种匹伐他汀钙的制备方法
CN103694228B (zh) * 2013-12-18 2018-08-28 北京华禧联合科技发展有限公司 一种制备匹伐他汀钙关键中间体的方法
CA2954215A1 (en) 2014-07-09 2016-01-14 Lupin Limited Polymorphic forms of pitavastatin sodium
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
SG11202107614PA (en) 2019-01-18 2021-08-30 Astrazeneca Ab Pcsk9 inhibitors and methods of use thereof
PL4566591T3 (pl) 2023-12-07 2026-04-07 Krka, D.D., Novo Mesto Stała farmaceutyczna postać dawkowania zawierająca ezetymib i pitawastatynę
WO2025168652A1 (en) 2024-02-05 2025-08-14 Astrazeneca Ab Azd-0780 in combination with a statin for use in lowering ldl-c levels and treating cardiovacular diseases
TW202602886A (zh) 2024-03-20 2026-01-16 瑞典商阿斯特捷利康公司 Ｐｃｓｋ９抑制劑及其使用方法
TW202539678A (zh) 2024-03-20 2025-10-16 瑞典商阿斯特捷利康公司 Ｐｃｓｋ９抑制劑及其使用方法
TW202602866A (zh) 2024-03-20 2026-01-16 瑞典商阿斯特捷利康公司 Ｐｃｓｋ９抑制劑及其使用方法
WO2025238159A1 (en) 2024-05-16 2025-11-20 Astrazeneca Ab Combination therapy comprising azd0780 and ezetimibe

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU204253B (en) * 1982-11-22 1991-12-30 Sandoz Ag Process for producing mevalonolactone analogues and derivatives and pharmaceutical compositions containing them
FI860755A0 (fi) * 1984-06-22 1986-02-20 Sandoz Ag Pyrazolanaloger av mevolonolakton och deras derivat, foerfaranden foer deras framstaellning samt deras andvaendning.
US4647576A (en) * 1984-09-24 1987-03-03 Warner-Lambert Company Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis
US4761419A (en) * 1987-12-07 1988-08-02 Warner-Lambert Company 6-(((substituted)quinolinyl)ethyl)-and ethenyl)tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis

Also Published As

Publication number Publication date
GR3015186T3 (en) 1995-05-31
EP0304063A2 (en) 1989-02-22
CA1336714C (en) 1995-08-15
HU211700A9 (en) 1995-12-28
DE3852243T2 (de) 1995-06-14
ATE114645T1 (de) 1994-12-15
EP0304063A3 (en) 1990-10-03
DE3852243D1 (de) 1995-01-12
EP0304063B1 (en) 1994-11-30

Similar Documents

Publication Publication Date Title
ES2067460T3 (es) Mevalonolactonas de tipo quinolina.
TW238300B (es)
MY100972A (en) Indene analogs of mevalonolactone and derivatives thereof
JPS5630964A (en) Novel substituted quinolinecarboxylic acid and its preparation
ES8400390A1 (es) Un procedimiento para la preparacion de derivados de 2-fenileta-nolamina.
EP0093593A3 (en) Pyridine compounds
GB2211186B (en) Chemical compounds
ES8403099A1 (es) Un procedimiento para la preparacion de derivados de etanolamina.
ES8403098A1 (es) Un procedimiento para la preparacion de derivados de etanolamina.
EP0239064A3 (en) Herbicidal compounds, their production and use
EP0108547A3 (en) 1-bromoethyl ethyl carbonate and its use in the preparation of 1'-ethoxy-carbonyloxyethyl esters of penicillins and novel intermediates, methods for its preparation and 1-bromoethylchloroformate and 1-bromoethylbromoformate obtained as intermediates
IE811308L (en) Anti-protozoal compositions
JPS56140984A (en) Substituted acetanilide compound, its preparation and herbicide containing the same as active constituent
HUT43598A (en) Process for production of derivatives of new 4-hidroxiquinoline carbonic acid and medical compound containing thereof
DK460585A (da) Mellemprodukter til fremstilling af prostatriensyrederivater
EP0094612A3 (en) Novel alkyloxazolylacetic acid derivative, processes for preparation and pharmaceutical compositions containing same
GB9324871D0 (en) Novel compounds
DE3362036D1 (en) Ketene-o,o-acetates and process for their preparation
IL74633A (en) Synergistic herbicidal compositions comprising trimethylsulphonium salt of n-phosphonomethyl-glycine and 1-m-trifluoromethyl-phenyl-3-chloro-4-chloromethyl-2-pyrrolidone
ES8604503A2 (es) Procedimiento de obtencion de sulfonamidinas
ATE74604T1 (de) Substituierte pyrimidochinoxaline.
ES8304546A1 (es) Un procedimiento de preparacion de zomepirac y sus analogos.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 304063

Country of ref document: ES